id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-N-4203-0034,FDA,FDA-2019-N-4203,"Advisory Committee; Bone, Reproductive and Urologic Drugs Advisory Committee; Change of Name and Function; Technical Amendment",Rule,Final Rule,2022-03-23T04:00:00Z,2022,3,2022-03-23T04:00:00Z,,2022-03-23T13:16:06Z,2022-05965,0,0,0900006484fdacce
FDA-2019-N-4203-0033,FDA,FDA-2019-N-4203,"Advisory Committee; Bone, Reproductive and Urologic Drugs Advisory Committee; Renewal",Notice,Advisory Committee,2020-12-11T05:00:00Z,2020,12,2020-12-11T05:00:00Z,,2020-12-11T14:22:38Z,2020-27289,0,0,0900006484998591
FDA-2019-N-4203-0001,FDA,FDA-2019-N-4203,"Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of
Meeting; Establishment of a Public Docket; Request for Comments",Notice,Meeting,2019-09-24T04:00:00Z,2019,9,2019-09-24T04:00:00Z,2019-10-29T03:59:59Z,2019-10-30T01:02:29Z,2019-20656,0,0,0900006483fbc72a